BRPI1006134A2 - anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada. - Google Patents

anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.

Info

Publication number: BRPI1006134A2
Authority: BR; Brazil
Prior art keywords: antibody; functional; fragment; polynucleotide; vector
Prior art date: 2009-04-09

Application number

BRPI1006134A

Other languages

English (en)

Inventor

Eisuke Tsuda

Makiko Nakayama

Takeshi Takizawa

Yoshiharu Hiruma

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-09

Filing date

2010-04-07

Publication date

2016-02-23

2010-04-07 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2016-02-23 Publication of BRPI1006134A2 publication Critical patent/BRPI1006134A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI1006134A 2009-04-09 2010-04-07 anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada. BRPI1006134A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2009094613		2009-04-09
PCT/JP2010/056294 WO2010117011A1 (ja)	2009-04-09	2010-04-07	抗Ｓｉｇｌｅｃ－１５抗体

Publications (1)

Publication Number	Publication Date
BRPI1006134A2 true BRPI1006134A2 (pt)	2016-02-23

Family

ID=42936292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1006134A BRPI1006134A2 (pt)	2009-04-09	2010-04-07	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.

Country Status (19)

Country	Link
US (3)	US8575316B2 (pt)
EP (2)	EP2377932B1 (pt)
JP (2)	JP5653909B2 (pt)
KR (1)	KR101690340B1 (pt)
CN (2)	CN106317224B (pt)
AU (2)	AU2010235453B2 (pt)
BR (1)	BRPI1006134A2 (pt)
CA (1)	CA2750836C (pt)
CO (1)	CO6420359A2 (pt)
ES (1)	ES2840923T3 (pt)
IL (2)	IL213943A (pt)
MX (2)	MX2011007342A (pt)
MY (1)	MY152033A (pt)
NZ (2)	NZ605450A (pt)
RU (2)	RU2539790C2 (pt)
SG (2)	SG172419A1 (pt)
TW (1)	TWI468177B (pt)
WO (1)	WO2010117011A1 (pt)
ZA (1)	ZA201104545B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8168181B2 (en)	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
AU2007215334B2 (en)	2006-02-13	2013-11-21	Daiichi Sankyo Company, Limited	Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP2907826B1 (en) *	2007-10-11	2018-05-30	Daiichi Sankyo Company, Limited	Antibody targeting osteoclast-related protein siglec-15
KR101690340B1 (ko)	2009-04-09	2016-12-27	다이이찌 산쿄 가부시키가이샤	항 Ｓｉｇｌｅｃ-15 항체
AU2011313596A1 (en)	2010-10-05	2013-04-11	Daiichi Sankyo Company, Limited	Antibody targeting osteoclast-related protein Siglec-15
WO2013034660A1 (en) *	2011-09-09	2013-03-14	Medimmune Limited	Anti-siglec-15 antibodies and uses thereof
BR112014024267A8 (pt) *	2012-03-30	2017-07-25	Daiichi Sankyo Co Ltd	anticorpo ou um fragmento de ligação de antígeno do anticorpo, composição farmacêutica, usos de pelo menos um dos anticorpos ou fragmentos de ligação de antígeno e de uma composição, polinucleotídeo, vetor, e, célula hospedeira transformada
WO2013147213A1 (ja)	2012-03-30	2013-10-03	第一三共株式会社	ＣＤＲ改変抗Ｓｉｇｌｅｃ－１５抗体
EP2875051B1 (en) *	2012-07-19	2019-02-20	Daiichi Sankyo Company, Limited	Anti-siglec-15 antibodies
WO2015046505A1 (ja)	2013-09-30	2015-04-02	第一三共株式会社	抗ｌｐｓｏ１１抗体
JP2017523148A (ja) *	2014-06-18	2017-08-17	第一三共株式会社	骨形成不全症の治療に使用するための抗Ｓｉｇｌｅｃ−１５抗体
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA2990572C (en)	2015-06-29	2022-07-26	Daiichi Sankyo Company, Limited	Method for selectively manufacturing antibody-drug conjugate
RU2759334C2 (ru) *	2016-09-21	2021-11-12	Нексткьюр, Инк.	Антитела против siglec-15 и способы их применения
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
TWI782000B (zh)	2017-03-30	2022-11-01	日商第一三共股份有限公司	抗ｇｐｒ２０抗體、其製造方法及其應用
EP3646885A4 (en) *	2017-06-30	2021-04-28	National University Corporation Hokkaido University	MEDICINAL PRODUCTS AGAINST OSTEOPOROSIS IN CHILDREN WITHOUT CAUSING GROWTH DISORDERS
TWI818916B (zh)	2017-07-27	2023-10-21	日商第一三共股份有限公司	抗ｃｄ１４７抗體、及其用途與製造方法
TW202428618A (zh)	2018-05-31	2024-07-16	日商第一三共股份有限公司	抗人類tlr7抗體、其用途及醫藥組成物
US20210169852A1 (en)	2018-07-27	2021-06-10	Daiichi Sankyo Company, Limited	Protein recognizing drug moiety of antibody-drug conjugate
CN111378043B (zh) *	2020-02-19	2021-02-09	南京医科大学	一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN113817057B (zh) *	2020-06-19	2024-02-20	盛禾(中国)生物制药有限公司	一种抗siglec15抗体及其应用
CN112159475B (zh) *	2020-10-10	2021-04-30	南京凯地生物科技有限公司	Siglec-15单克隆抗体及其应用
CN114525256A (zh) *	2020-10-30	2022-05-24	未来智人再生医学研究院(广州)有限公司	一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
CN114591434B (zh) *	2021-04-30	2023-02-28	杭州邦顺制药有限公司	抗Siglec15抗体及其制备方法和用途
CN113577283A (zh) *	2021-07-19	2021-11-02	河北医科大学第三医院	Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN114807052A (zh) *	2022-06-07	2022-07-29	江苏亲科生物研究中心有限公司	Siglec15单克隆抗体及其制备方法和用途
CN117736324B (zh) *	2022-09-22	2024-06-28	北京东方百泰生物科技股份有限公司	一种抗Siglec-15单克隆抗体的纯化方法
WO2024040195A1 (en)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1992020791A1 (en)	1990-07-10	1992-11-26	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1993019172A1 (en)	1992-03-24	1993-09-30	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
CA2177367A1 (en)	1993-12-03	1995-06-08	Andrew David Griffiths	Recombinant binding proteins and peptides
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de)	1996-12-20	1998-06-25	Hoechst Ag	Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
ATE328006T1 (de) *	1997-04-15	2006-06-15	Sankyo Co	Neues protein und verfahren zu dessen herstellung
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
JP4368530B2 (ja)	1999-04-09	2009-11-18	協和発酵キリン株式会社	免疫機能分子の活性を調節する方法
WO2002031140A1 (fr)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Cellules produisant des compositions d'anticorps
US7608704B2 (en)	2000-11-08	2009-10-27	Incyte Corporation	Secreted proteins
WO2002038602A2 (en)	2000-11-08	2002-05-16	Incyte Genomics, Inc.	Secreted proteins
JPWO2002064771A1 (ja)	2001-02-15	2004-06-17	持田製薬株式会社	活性化白血球に特異的な新規細胞接着分子
CN1547486A (zh)	2001-06-26	2004-11-17		抗opgl抗体
AU2002364699A1 (en)	2001-11-13	2003-06-17	Incyte Genomics, Inc.	Receptors and membrane-associated proteins
US7193069B2 (en)	2002-03-22	2007-03-20	Research Association For Biotechnology	Full-length cDNA
EP2314316A1 (en)	2002-04-05	2011-04-27	Amgen, Inc	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
DK1583830T3 (da)	2003-01-07	2007-01-15	Symphogen As	Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner
TWI359026B (en)	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
US7405037B2 (en)	2004-05-07	2008-07-29	Lonza Walkersville, Inc.	Methods and tools for detecting collagen degradation
JP4604184B2 (ja) *	2005-07-12	2010-12-22	独立行政法人産業技術総合研究所	新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) *	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
AU2007215334B2 (en)	2006-02-13	2013-11-21	Daiichi Sankyo Company, Limited	Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP2907826B1 (en)	2007-10-11	2018-05-30	Daiichi Sankyo Company, Limited	Antibody targeting osteoclast-related protein siglec-15
KR101690340B1 (ko)	2009-04-09	2016-12-27	다이이찌 산쿄 가부시키가이샤	항 Ｓｉｇｌｅｃ-15 항체

2010
- 2010-04-07 KR KR1020117015666A patent/KR101690340B1/ko active IP Right Grant
- 2010-04-07 US US13/143,253 patent/US8575316B2/en active Active
- 2010-04-07 EP EP10761710.2A patent/EP2377932B1/en active Active
- 2010-04-07 ES ES10761710T patent/ES2840923T3/es active Active
- 2010-04-07 WO PCT/JP2010/056294 patent/WO2010117011A1/ja active Application Filing
- 2010-04-07 CN CN201610749543.2A patent/CN106317224B/zh not_active Expired - Fee Related
- 2010-04-07 MX MX2011007342A patent/MX2011007342A/es active IP Right Grant
- 2010-04-07 SG SG2011047412A patent/SG172419A1/en unknown
- 2010-04-07 CA CA2750836A patent/CA2750836C/en active Active
- 2010-04-07 BR BRPI1006134A patent/BRPI1006134A2/pt not_active Application Discontinuation
- 2010-04-07 AU AU2010235453A patent/AU2010235453B2/en not_active Ceased
- 2010-04-07 EP EP20165057.9A patent/EP3699277A1/en not_active Withdrawn
- 2010-04-07 RU RU2011128332/10A patent/RU2539790C2/ru active
- 2010-04-07 MX MX2014002553A patent/MX343049B/es unknown
- 2010-04-07 NZ NZ605450A patent/NZ605450A/en not_active IP Right Cessation
- 2010-04-07 SG SG10201401331TA patent/SG10201401331TA/en unknown
- 2010-04-07 MY MYPI2011002935 patent/MY152033A/en unknown
- 2010-04-07 NZ NZ593550A patent/NZ593550A/xx not_active IP Right Cessation
- 2010-04-07 CN CN201080004195.7A patent/CN102272306B/zh not_active Expired - Fee Related
- 2010-04-07 JP JP2011508375A patent/JP5653909B2/ja active Active
- 2010-04-08 TW TW99110882A patent/TWI468177B/zh not_active IP Right Cessation
2011
- 2011-06-20 ZA ZA2011/04545A patent/ZA201104545B/en unknown
- 2011-07-05 IL IL213943A patent/IL213943A/en active IP Right Grant
- 2011-07-08 CO CO11085127A patent/CO6420359A2/es active IP Right Grant
2013
- 2013-07-17 AU AU2013207589A patent/AU2013207589B2/en not_active Ceased
- 2013-09-30 US US14/041,479 patent/US9079959B2/en active Active
2014
- 2014-11-19 JP JP2014234461A patent/JP6210966B2/ja active Active
- 2014-11-24 RU RU2014147188A patent/RU2014147188A/ru not_active Application Discontinuation
2015
- 2015-06-05 US US14/731,519 patent/US9751944B2/en active Active
2017
- 2017-05-28 IL IL252561A patent/IL252561B/en active IP Right Grant

Also Published As

Publication number	Publication date
JP2015096510A (ja)	2015-05-21
IL252561A0 (en)	2017-07-31
CO6420359A2 (es)	2012-04-16
US20150299318A1 (en)	2015-10-22
AU2013207589B2 (en)	2016-04-07
CN102272306A (zh)	2011-12-07
CA2750836A1 (en)	2010-10-14
KR20120034587A (ko)	2012-04-12
US8575316B2 (en)	2013-11-05
JP6210966B2 (ja)	2017-10-11
TWI468177B (zh)	2015-01-11
CN106317224B (zh)	2020-05-12
CN102272306B (zh)	2017-12-26
SG172419A1 (en)	2011-07-28
WO2010117011A1 (ja)	2010-10-14
MY152033A (en)	2014-08-15
JP5653909B2 (ja)	2015-01-14
KR101690340B1 (ko)	2016-12-27
US20140065146A1 (en)	2014-03-06
EP3699277A1 (en)	2020-08-26
IL213943A0 (en)	2011-07-31
NZ605450A (en)	2014-07-25
MX343049B (es)	2016-10-21
SG10201401331TA (en)	2014-10-30
EP2377932A4 (en)	2013-04-24
RU2014147188A (ru)	2016-06-10
IL213943A (en)	2017-06-29
MX2011007342A (es)	2011-07-21
ES2840923T3 (es)	2021-07-07
RU2011128332A (ru)	2013-01-20
CA2750836C (en)	2018-05-01
US20110268733A1 (en)	2011-11-03
US9751944B2 (en)	2017-09-05
JPWO2010117011A1 (ja)	2012-10-18
EP2377932A1 (en)	2011-10-19
NZ593550A (en)	2013-11-29
TW201039852A (en)	2010-11-16
RU2014147188A3 (pt)	2018-06-27
IL252561B (en)	2019-02-28
CN106317224A (zh)	2017-01-11
US9079959B2 (en)	2015-07-14
AU2010235453A1 (en)	2011-07-28
AU2010235453B2 (en)	2013-10-03
RU2539790C2 (ru)	2015-01-27
ZA201104545B (en)	2012-03-28
EP2377932B1 (en)	2020-11-18

Publication	Publication Date	Title
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112012006326A2 (pt)	2016-11-16	anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
BRPI1007005A2 (pt)	2016-03-22	anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BR112012003792A2 (pt)	2016-04-19	gel tópico, e, uso do gel tópico.
BRPI0909084A2 (pt)	2015-08-11	Composição líquida, e, composto de peptídeo.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
FR2943680B1 (fr)	2012-12-28	Composition de caoutchoux et pneumatique utilisant cette composition.
BR112014000263A2 (pt)	2017-02-14	anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
UA113712C2 (xx)	2017-02-27	Антитіло до fap і способи його застосування
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0914691A2 (pt)	2015-10-20	composto imunoadjuvante, composição, uso de um composto imunoadjuvante, ácido nucléico, vetor recombinante, e, célula hospedeira
BR112012003800A2 (pt)	2016-11-22	composição, peptídeo, e formulação farmacêutica.
BRPI0910557A2 (pt)	2015-09-29	composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI0923199A2 (pt)	2016-02-16	métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0819299A2 (pt)	2014-10-07	Uso de composição, e, composição contendo proteína
BR112014016076A2 (pt)	2017-06-13	peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica
BRPI0814420A2 (pt)	2015-11-17	composição, e, uso de álcool alcoxilado.
BR112014017518A8 (pt)	2017-07-04	anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
BR112012031226A2 (pt)	2018-03-06	composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0814296A2 (pt)	2014-10-21	Polipeptídeo isolado, seqüência de nucleotídeos, vetor, célula hospedeira, e, uso do polipeptídeo, da seqüência de nucleotídeos, do vetor ou da célula hospedeira

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-09	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.
2020-06-23	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-09-15	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-01-05	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements